Faeth Therapeutics (FTH) Share-based Compensation (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Share-based Compensation came in at $57.4 million in Q1 2026, up 12351.19% YoY from N/an in Q1 2025, and up 19357.63% on a QoQ basis from $295000.0 in Q4 2025.
Faeth Therapeutics (FTH) Share-based Compensation (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Share-based Compensation data on file, last reported at $57.4 million in Q1 2026.
- Quarterly Share-based Compensation rose 12351.19% year-over-year to $57.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.4 million (up 7804.7% YoY) and the FY2025 annual result came in at $1.3 million, down 15.07% from the prior year.
- Share-based Compensation improved to $57.4 million in Q1 2026, from $295000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $57.4 million in Q1 2026 to a low of -$3.3 million in Q4 2023.
- A 5-year average of $3.8 million and a median of $1.0 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation sank 330.66% — and 2026, when it jumped 12351.19%.
- Tracing FTH's Share-based Compensation over 5 years: stood at $1.4 million in 2022, then slumped by 330.66% to -$3.3 million in 2023, then climbed by 16.65% to -$2.7 million in 2024, then soared by 110.79% to $295000.0 in 2025, then surged by 19357.63% to $57.4 million in 2026.
- The last three Share-based Compensation figures came in at $57.4 million (Q1 2026), $295000.0 (Q4 2025), and $254000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | - |
| 10 | Faeth Therapeutics | 179.40 Mn | 179.40 Mn | - | 62.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.20 Mn |
| Jun 30, 2026 | 62.20 Mn |
| Mar 31, 2026 | 57.40 Mn |
| Mar 31, 2026 | 57.40 Mn |
| Dec 31, 2025 | 295,000.00 |
| Dec 31, 2025 | 295,000.00 |
| Sep 30, 2025 | 254,000.00 |
| Sep 30, 2025 | 254,000.00 |
| Jun 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 461,000.00 |
| Mar 31, 2025 | 461,000.00 |
| Dec 31, 2024 | -2.73 Mn |
| Dec 31, 2024 | -2.73 Mn |
| Sep 30, 2024 | 733,000.00 |
| Sep 30, 2024 | 733,000.00 |
| Jun 30, 2024 | 795,000.00 |
| Jun 30, 2024 | 795,000.00 |
| Mar 31, 2024 | 1.22 Mn |
| Mar 31, 2024 | 1.22 Mn |